Scarica l'app Stockscreener
162.00
3.51%
-5.90
Dopo l'orario di chiusura:
162.00
Precedente Chiudi:
$167.90
Aprire:
$166.18
Volume 24 ore:
2.00M
Relative Volume:
1.12
Capitalizzazione di mercato:
$27.04B
Reddito:
$16.63B
Utile/perdita netta:
$1.39B
Rapporto P/E:
20.08
EPS:
8.0674
Flusso di cassa netto:
$2.12B
1 W Prestazione:
-6.46%
1M Prestazione:
-0.17%
6M Prestazione:
-30.11%
1 anno Prestazione:
+18.25%
Intervallo 1D:
$161.75
$167.09
Intervallo di 1 settimana:
$161.75
$171.97
Portata 52W:
$136.41
$247.04
Iqvia Holdings Inc Stock (IQV) Company Profile
Nome
Iqvia Holdings Inc
Settore
Industria
Telefono
919-998-2000
Indirizzo
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
162.00 | 28.02B | 16.63B | 1.39B | 2.12B | 8.0674 |
TMO
Thermo Fisher Scientific Inc
|
448.18 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.81 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.21 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
338.64 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.08 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2026-03-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2026-03-03 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-11-13 | Iniziato | BMO Capital Markets | Outperform |
| 2025-11-03 | Downgrade | TD Cowen | Buy → Hold |
| 2025-10-29 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-09 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2025-09-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-04-25 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-02-03 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-20 | Iniziato | Stephens | Overweight |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-07-24 | Downgrade | Jefferies | Buy → Hold |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-02-13 | Iniziato | BTIG Research | Buy |
| 2023-11-02 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-03-17 | Iniziato | Truist | Buy |
| 2022-12-06 | Iniziato | Cowen | Outperform |
| 2022-11-17 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-07-15 | Iniziato | SVB Leerink | Outperform |
| 2022-05-24 | Iniziato | Guggenheim | Buy |
| 2022-04-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-16 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2021-03-08 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2020-07-07 | Iniziato | Stephens | Equal-Weight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | CFRA | Sell → Hold |
| 2019-11-14 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2019-06-21 | Aggiornamento | Mizuho | Neutral → Buy |
| 2019-05-28 | Iniziato | SVB Leerink | Outperform |
| 2019-01-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-10-02 | Reiterato | Robert W. Baird | Outperform |
| 2018-07-25 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2018-07-25 | Reiterato | Stifel | Buy |
| 2018-07-03 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-04-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-03-07 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-01-19 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Iqvia Holdings Inc Borsa (IQV) Ultime notizie
IQVIA Holdings Inc (IQV) Stock Down 3.5% -- Now Undervalued? GF Score: 86/100 - GuruFocus
IQVIA CEO to Speak at Jefferies Global Healthcare Conference - pharmiweb.com
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term - Yahoo Finance
What Makes IQVIA Holdings (IQV) an Investment Bet? - Insider Monkey
IQVIA Holdings, Inc. (IQV): Analyst Consensus Reveals 36% Upside Potential for Healthcare Giant - DirectorsTalk Interviews
Liquidity Mapping Around (IQV) Price Events - Stock Traders Daily
IQVIA signals raised 2026 adjusted EPS outlook to $12.65-$12.95 while reaffirming $17.150B-$17.350B revenue - MSN
Are Wall Street analysts predicting IQVIA Holdings stock will climb or sink? - MSN
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Beta Bionics, Inc. (BBNX) and Twist Bioscience (TWST) - The Globe and Mail
IQV News | IQVIA HOLDINGS INC (NYSE:IQV) - ChartMill
IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IQVIA Holdings Inc stock (US46266C1053): data-driven healthcare group in focus after latest earnings - AD HOC NEWS
Are Wall Street Analysts Predicting IQVIA Holdings Stock Will Climb or Sink? - Barchart
IQVIA’s SWOT analysis: healthcare stock faces margin pressures - Investing.com
IQVIA: The Market May Be Missing The AI And Data Story (NYSE:IQV) - Seeking Alpha
Research Alert: CFRA Moderates Rating On Shares Of Iqvia Holdings Inc. To Hold From Buy - Moomoo
IQVIA Holdings stock (US46266C1053): latest earnings highlight data strength and AI ambitions - AD HOC NEWS
IQVIA Signals Confidence with $3.2 Billion Share Repurchase War Chest - BriefGlance
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
IQVIA (IQV) Fell Despite Strong Fundamentals - Insider Monkey
IQVIA Holdings, Inc. (IQV) Stock Analysis: Growth Potential and Analyst Consensus Point to 35% Upside - DirectorsTalk Interviews
Mid-Cap Stocks: IQVIA (IQV) and First Citizens (FCNCA) Sell SignalsNews and Statistics - IndexBox
IQVIA Holdings (IQV) Q1 earnings and revenues beat estimates - MSN
IQVIA Holdings stock (US46266C1053): earnings, data growth and what investors watch now - AD HOC NEWS
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know - Yahoo Finance
IQVIA Holdings Inc stock (US46266C1053): earnings momentum and AI narrative draw fresh attention - AD HOC NEWS
Catholic Responsible Investments Equity Index Fund's IQVIA Holdings Inc(IQV) Holding History - GuruFocus
Is There Now An Opportunity In IQVIA Holdings Inc. (NYSE:IQV)? - Moomoo
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Will IQVIA's (IQV) AI‑Driven Biosimilar Partnership with Kexing Reshape Its Long‑Term Narrative? - Yahoo Finance
IQVIA’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
IQVIA Holdings earnings preview: What to expect - MSN
BofA Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $245 - Moomoo
IQVIA Holdings stock (US46266C1053): Expands AI-powered biosimilars deal with Kexing Biopharm - AD HOC NEWS
IQVIA Holdings, Inc. Common Stock (NY: IQV - FinancialContent
IQVIA expands collaboration with Kexing Biopharm on biosimilars - Investing.com UK
Why (IQV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
IQVIA expands collaboration with Kexing Biopharm on biosimilars By Investing.com - Investing.com Nigeria
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
AI-powered trials to speed global biosimilar drugs in IQVIA-Kexing pact - Stock Titan
IQVIA Holdings stock (US46266C1053): Global leader in healthcare data analytics - AD HOC NEWS
IQVIA Q1 2026 slides: earnings beat drives guidance raise By Investing.com - Investing.com Nigeria
IQVIA Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges By Investing.com - Investing.com South Africa
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges - Investing.com
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term - Yahoo Finance
IQVIA Holdings | 4: Statement of changes in beneficial ownership of securities-Director GOGGINS COLLEEN A - Moomoo
IQVIA (NYSE: IQV) director granted 171 deferred shares at $178.64 - Stock Titan
IQVIA (NYSE: IQV) director Colleen Goggins receives 214 Deferred Shares grant - Stock Titan
IQVIA (NYSE: IQV) director Jim Fasano receives 228 deferred share award - Stock Titan
Iqvia Holdings Inc Azioni (IQV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):